AlphaMadera's AlphaVal page computes Hims & Hers Health, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag HIMS as undervalued, fairly valued, or overvalued.

What is Hims & Hers Health, Inc.'s fair value?

Fair value for HIMS is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value HIMS?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from HIMS's most recent reported fundamentals.

HIMS - Hims & Hers Health, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $26.91 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Strong

Trading 362.6% above fair value

Current Price $31.12

Bear Case $0.00 100.0% downside ($0.00 - $31.12) / $31.12 = -100.0% 12% stage 1 growth, 12% discount

Fair Value $6.73 78.4% downside ($6.73 - $31.12) / $31.12 = -78.4% 20% stage 1 growth, 12% discount

Bull Case $0.00 100.0% downside ($0.00 - $31.12) / $31.12 = -100.0% 26% stage 1 growth, 12% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

20.0%

Discount Rate (WACC)

12.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (20% base case)

Terminal Value % of EV 0%

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $26.91 from 20 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $6.73 per share.

Warnings

⚠ Stock-based employee pay equals 105% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.

ℹ Wall Street's average price target is $26.91 (from 20 analysts). Our estimate is 100% below the consensus -- consider that gap carefully.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions